Atara Biotherapeutics Inc. (ATRA) 28.75 $ATRA
Atara Biotherapeutics' Collaborating Investigators to Present Data at the American Society of Hematology Annual Meeting 2014
GlobeNewswire - Thu Nov 06, 8:45AM CST
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present at the Annual Meeting of the American Society of Hematology (ASH) 2014. Data will be presented regarding ongoing clinical studies with cytomegalovirus (CMV) T cell therapy. The meeting will be held in San Francisco December 6-9th, 2014.
ATRA: 28.75 (+3.95)
Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
GlobeNewswire - Wed Oct 22, 5:50AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM 434, an Activin inhibitor, in patients with ovarian cancer and other solid tumors. The study is designed to assess the safety, tolerability and efficacy of STM 434 as a single therapy and in combination with liposomal doxorubicin. Further information regarding the clinical study can be found at http://www.clinicaltrials.gov/ct2/show/NCT02262455.
ATRA: 28.75 (+3.95)
Photo Release -- Nasdaq Welcomes Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to The Nasdaq Stock Market
GlobeNewswire - Thu Oct 16, 9:45AM CDT
Nasdaq (Nasdaq:NDAQ) announced that trading of Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company, commenced on The Nasdaq Stock Market on October 16, 2014.
ATRA: 28.75 (+3.95), NDAQ: 43.88 (-0.02)
Atara Biotherapeutics (Nasdaq: ATRA) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
GlobeNewswire - Thu Oct 16, 5:41AM CDT
--
ATRA: 28.75 (+3.95), NDAQ: 43.88 (-0.02)
Atara Biotherapeutics Announces Pricing of Its Initial Public Offering
GlobeNewswire - Wed Oct 15, 10:10PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol "ATRA" on October 16, 2014. In addition, Atara has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Atara at the initial public offering price to cover over-allotments, if any. The offering is expected to close on October 21, 2014, subject to customary closing conditions.
ATRA: 28.75 (+3.95)
IPO Stock Watch: Biotech Forward Pharma Falls On IPO
at Investor's Business Daily - Wed Oct 15, 3:06PM CDT
Forward Pharma, the largest biotech IPO this year, tanked on its first day of trading. Denmark-based Forward Pharma (FWP) raised $221 million by pricing 10.5 million shares at 21, the midpoint of its 20-22 range. The stock was trading near 17.50,...
DM: 33.04 (+0.79), BIIB: 320.75 (-2.72), KITE: 45.99 (+2.35), FWP: 21.05 (+0.05), XENE: 13.29 (+1.32), ATRA: 28.75 (+3.95), VBAY: (), GWB: 20.04 (+0.20)
Biotechs lead list of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 5:46PM CDT
Four more biotech IPOs are scheduled to debut this week. Forward Pharma (FWP) looks to raise $200 mil by offering 9.5 mil shares at a price range of 20-22. Atara Biotherapeutics (ATRA) plans to raise $75 mil by selling 5 mil shares at 14-16. Xenon...
FWP: 21.05 (+0.05), XENE: 13.29 (+1.32), ATRA: 28.75 (+3.95), VBAY: ()
IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 33.04 (+0.79), BIIB: 320.75 (-2.72), FWP: 21.05 (+0.05), KITE: 45.99 (+2.35), XENE: 13.29 (+1.32), MRK: 59.34 (+0.08), CFG: 23.97 (-0.33), ZAYO: 23.59 (+0.01), ATRA: 28.75 (+3.95), TEVA: 57.70 (-1.02), VBAY: (), GWB: 20.04 (+0.20)
Atara Biotherapeutics Announces Immunotherapy Alliance With Memorial Sloan Kettering Cancer Center
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Atara Biotherapeutics (Atara) today announced that they have entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. Under the terms of the agreement, Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies consisting of:
ATRA: 28.75 (+3.95)
IPO Calendar: Biotechs Sizzle With 7 New Issues
at Investor's Business Daily - Mon Jul 21, 1:00PM CDT
With 40 biotech IPOs completed this year, seven more are planned as the health care sector overall continues to dominate new issues. Biotech companies account for half the 14 initial public offerings planned for this week. The best performing IPO...
XENT: 18.04 (+0.05), SAGE: 38.72 (-0.28), INNL: 7.72 (+0.92), TSQ: 12.58 (+0.09), LOCO: 36.60 (-0.70), ATRA: 28.75 (+3.95), OCUL: 15.53 (+0.02), OEC: 15.00 (+0.05)
Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding
ECYT: 6.03 (-0.46), DRNA: 9.11 (+0.97), SGEN: 36.05 (+1.20), ATRA: 28.75 (+3.95), ENTA: 43.33 (-0.17), ALKS: 51.00 (-0.03), NVS: 91.76 (-0.27)
Atara Biotherapeutics' Collaborating Investigators to Present Data at the American Society of Hematology Annual Meeting 2014
GlobeNewswire - Thu Nov 06, 8:45AM CST
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present at the Annual Meeting of the American Society of Hematology (ASH) 2014. Data will be presented regarding ongoing clinical studies with cytomegalovirus (CMV) T cell therapy. The meeting will be held in San Francisco December 6-9th, 2014.
ATRA: 28.75 (+3.95)
Atara Biotherapeutics Doses First Patient in Phase 1 Clinical Study of STM 434, an Activin Inhibitor
GlobeNewswire - Wed Oct 22, 5:50AM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM 434, an Activin inhibitor, in patients with ovarian cancer and other solid tumors. The study is designed to assess the safety, tolerability and efficacy of STM 434 as a single therapy and in combination with liposomal doxorubicin. Further information regarding the clinical study can be found at http://www.clinicaltrials.gov/ct2/show/NCT02262455.
ATRA: 28.75 (+3.95)
Photo Release -- Nasdaq Welcomes Atara Biotherapeutics, Inc. (Nasdaq: ATRA) to The Nasdaq Stock Market
GlobeNewswire - Thu Oct 16, 9:45AM CDT
Nasdaq (Nasdaq:NDAQ) announced that trading of Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company, commenced on The Nasdaq Stock Market on October 16, 2014.
ATRA: 28.75 (+3.95), NDAQ: 43.88 (-0.02)
Atara Biotherapeutics (Nasdaq: ATRA) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO
GlobeNewswire - Thu Oct 16, 5:41AM CDT
--
ATRA: 28.75 (+3.95), NDAQ: 43.88 (-0.02)
Atara Biotherapeutics Announces Pricing of Its Initial Public Offering
GlobeNewswire - Wed Oct 15, 10:10PM CDT
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $11.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol "ATRA" on October 16, 2014. In addition, Atara has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock from Atara at the initial public offering price to cover over-allotments, if any. The offering is expected to close on October 21, 2014, subject to customary closing conditions.
ATRA: 28.75 (+3.95)
IPO Stock Watch: Biotech Forward Pharma Falls On IPO
at Investor's Business Daily - Wed Oct 15, 3:06PM CDT
Forward Pharma, the largest biotech IPO this year, tanked on its first day of trading. Denmark-based Forward Pharma (FWP) raised $221 million by pricing 10.5 million shares at 21, the midpoint of its 20-22 range. The stock was trading near 17.50,...
DM: 33.04 (+0.79), BIIB: 320.75 (-2.72), KITE: 45.99 (+2.35), FWP: 21.05 (+0.05), XENE: 13.29 (+1.32), ATRA: 28.75 (+3.95), VBAY: (), GWB: 20.04 (+0.20)
Biotechs lead list of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 5:46PM CDT
Four more biotech IPOs are scheduled to debut this week. Forward Pharma (FWP) looks to raise $200 mil by offering 9.5 mil shares at a price range of 20-22. Atara Biotherapeutics (ATRA) plans to raise $75 mil by selling 5 mil shares at 14-16. Xenon...
FWP: 21.05 (+0.05), XENE: 13.29 (+1.32), ATRA: 28.75 (+3.95), VBAY: ()
IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 33.04 (+0.79), BIIB: 320.75 (-2.72), FWP: 21.05 (+0.05), KITE: 45.99 (+2.35), XENE: 13.29 (+1.32), MRK: 59.34 (+0.08), CFG: 23.97 (-0.33), ZAYO: 23.59 (+0.01), ATRA: 28.75 (+3.95), TEVA: 57.70 (-1.02), VBAY: (), GWB: 20.04 (+0.20)
Atara Biotherapeutics Announces Immunotherapy Alliance With Memorial Sloan Kettering Cancer Center
GlobeNewswire - Tue Sep 23, 9:39AM CDT
Atara Biotherapeutics (Atara) today announced that they have entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies for the treatment of certain cancers and persistent viral infections. Under the terms of the agreement, Atara will have the option to acquire a worldwide license to three clinical stage T-cell therapies consisting of:
ATRA: 28.75 (+3.95)
IPO Calendar: Biotechs Sizzle With 7 New Issues
at Investor's Business Daily - Mon Jul 21, 1:00PM CDT
With 40 biotech IPOs completed this year, seven more are planned as the health care sector overall continues to dominate new issues. Biotech companies account for half the 14 initial public offerings planned for this week. The best performing IPO...
XENT: 18.04 (+0.05), SAGE: 38.72 (-0.28), INNL: 7.72 (+0.92), TSQ: 12.58 (+0.09), LOCO: 36.60 (-0.70), ATRA: 28.75 (+3.95), OCUL: 15.53 (+0.02), OEC: 15.00 (+0.05)
Biotech Funding Deals and Partnerships 2014: Analysis of 56 Recent Venture Capital and Corporate Capital Funding and Other Transactions
M2 - Wed Jun 25, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r6b8dm/biotech_funding) has announced the addition of the "Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions" report to their offering. Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic. Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector. Included in the report's coverage are the following data points - 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential - Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions) - Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions) - Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million - Number of Biotech Series A Companies by Indication Oncology, - Platform Discovery, Diagnostics, CNS, Autoimmune) - Biotech Total Deal Value, 2005-2012 - IPO Statistics - Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013 Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs. This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma. The following are among the companies covered in this report: - Abbott - AC Immune SA - Adimab - Aileron Therapeutics Inc. - Atara Biotherapeutics - Cellectis - Clarus Ventures - CoStim Pharmaceuticals - Covagen AG - Dicerna Pharmaceuticals Inc. - Editas Medicine - Enanta Pharmaceuticals Inc. - Endocyte Inc. - Mannkind Corp. - Melinta Therapeutics - Micromet - Novartis - OncoMed - Onyx Pharmaceuticals Inc. - Otonomy Inc. - Pharmasset - Seattle Genetics Inc. - Royalty Pharma - Roche - Sutro Biopharma Inc. - Thesan Pharmaceuticals Inc. - UCB Inc. - Voyager Therapeutics - Xenon Pharmaceuticals Inc. - Xoma Corp. For more information visit http://www.researchandmarkets.com/research/r6...ch_funding
ECYT: 6.03 (-0.46), DRNA: 9.11 (+0.97), SGEN: 36.05 (+1.20), ATRA: 28.75 (+3.95), ENTA: 43.33 (-0.17), ALKS: 51.00 (-0.03), NVS: 91.76 (-0.27)
